TNB Financial boosted its position in shares of Pfizer, Inc. (NYSE:PFE) by 14.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 92,372 shares of the biopharmaceutical company’s stock after buying an additional 11,361 shares during the period. TNB Financial’s holdings in Pfizer were worth $3,103,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Asset Planning Services Ltd. raised its stake in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 137 shares in the last quarter. D. Scott Neal Inc. raised its stake in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares in the last quarter. Orrstown Financial Services Inc. raised its stake in Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC purchased a new stake in Pfizer during the first quarter worth $121,000. Finally, Cascade Investment Advisors Inc. raised its stake in Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 2,200 shares in the last quarter. Institutional investors and hedge funds own 69.98% of the company’s stock.

Pfizer, Inc. (NYSE:PFE) opened at 33.48 on Monday. The firm’s 50-day moving average is $33.20 and its 200 day moving average is $33.25. Pfizer, Inc. has a one year low of $29.83 and a one year high of $37.39. The stock has a market cap of $199.80 billion, a P/E ratio of 28.18 and a beta of 1.01.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $0.69 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.02. Pfizer had a return on equity of 23.68% and a net margin of 13.76%. The business had revenue of $12.78 billion for the quarter, compared to analyst estimates of $13.09 billion. During the same quarter in the prior year, the firm posted $0.67 EPS. The business’s quarterly revenue was down 1.7% compared to the same quarter last year. On average, analysts anticipate that Pfizer, Inc. will post $2.55 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 1st. Shareholders of record on Friday, August 4th will be given a $0.32 dividend. The ex-dividend date is Wednesday, August 2nd. This represents a $1.28 annualized dividend and a yield of 3.82%. Pfizer’s dividend payout ratio is presently 108.48%.

TRADEMARK VIOLATION WARNING: This article was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/07/24/tnb-financial-has-3-10-million-position-in-pfizer-inc-pfe.html.

A number of analysts have weighed in on PFE shares. Cowen and Company set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, July 10th. Sanford C. Bernstein restated a “buy” rating and set a $35.00 price objective on shares of Pfizer in a research note on Monday, April 24th. Barclays PLC restated a “buy” rating and set a $38.00 price objective on shares of Pfizer in a research note on Wednesday, May 3rd. ValuEngine lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, BMO Capital Markets restated a “hold” rating and set a $33.00 price objective on shares of Pfizer in a research note on Thursday, April 27th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating and ten have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $37.68.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.